Contrast Induced Nephropathy Clinical Trial
Official title:
A Study to Evaluate the Effectiveness of Induced Diuresis With Matched Hydration Therapy Compared to Standard Overnight Hydration in the Prevention of Contrast Induced Nephropathy -MYTHOS Study
This study is being proposed with the objective to assess the potential benefits of induced diuresis by furosemide with matched hydration therapy compared to standard hydration in the prevention of contrast-induced nephropathy (CIN). It is expected that matched hydration will prove to be as effective as hydration alone, will avoid an overnight stay prior to the procedure, and thus will prove to be a less costly and more clinically manageable solution to the prevention of CIN.
Radiocontrast agents (contrast) are widely used in coronary and peripheral vascular
catheterization procedures. Although the use of these iodine-containing agents is vital for
these procedures, it can be associated with adverse side effects. CIN is one of the most
important adverse effects of contrast agents, and can cause substantial morbidity and
mortality.
Although the exact mechanisms remain unknown, intravenous hydration before the
catheterization procedure is the only current treatment that has been shown to reduce the
incidence of CIN. However, in patients with baseline impairments in renal function,
hydration is commonly performed at a rate significantly lower than that shown to provide
protection due to the fear of overhydration and pulmonary edema. Previous studies have used
diuretics to increase urine output and prevent overhydration. In addition to the benefit of
increased urine flow, loop diuretics, such as furosemide, should be expected to provide
additive benefit against another potential mechanism of CIN, medullary ischemia, as they
reduce sodium reabsorption, and consequentially oxygen consumption, of the kidney. While the
results of their use have been mixed, it appears that furosemide was deleterious in patients
who became dehydrated, i.e. those in whom the urine output was substantially greater than
the rate of hydration they received.
This problem may be overcome by a device, which is now available on the market, called the
RenalGuard System. The System is capable of delivering saline solution to a patient in an
amount matched to the volume of urine produced by the patient. The purpose of this matched
fluid replacement is to prevent hypovolemia that may lead to hypotension or fluid
overload.The aim of the study is to compare furosemide-induced diuresis with matched
hydration therapy compared to standard hydration.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00842868 -
The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases
|
N/A | |
Completed |
NCT00634491 -
Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy
|
Phase 2 | |
Terminated |
NCT00476619 -
Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial
|
Phase 4 | |
Recruiting |
NCT03121053 -
Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement
|
Phase 4 | |
Completed |
NCT02650336 -
Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial
|
N/A | |
Completed |
NCT01741896 -
Can Remote Ischaemic Preconditioning Reduce Contrast Induced Nephropathy in Patients Receiving Contrast for Computed Tomography?
|
N/A | |
Terminated |
NCT00575419 -
Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure
|
Phase 1 | |
Not yet recruiting |
NCT00392405 -
Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate
|
Phase 2 | |
Completed |
NCT00292487 -
Patients With Renal Impairment Undergoing CT
|
Phase 4 | |
Recruiting |
NCT04982419 -
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
|
Phase 2/Phase 3 | |
Completed |
NCT00770614 -
Hydration and Contrast-Induced Nephropathy in Primary Angioplasty
|
Phase 4 | |
Completed |
NCT01999517 -
Contrast Nephropathy and Nitrates
|
Phase 4 | |
Completed |
NCT00531765 -
Sodium Bicarbonate in Preventing Contrast Induced Nephropathy
|
N/A | |
Completed |
NCT00639912 -
Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction.
|
Phase 4 | |
Terminated |
NCT00494637 -
The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy
|
N/A | |
Completed |
NCT02516072 -
Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy
|
N/A | |
Active, not recruiting |
NCT01402232 -
REduction of rIsk for Contrast Induced Nephropathy
|
||
Recruiting |
NCT02113540 -
Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography
|
Phase 3 | |
Active, not recruiting |
NCT01456013 -
Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients
|
Phase 3 | |
Recruiting |
NCT01399203 -
Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention
|
N/A |